Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in persistent or chronic Immune Thrombocytopenia (LUNA 3)
NCT04562766Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2020
- Primary completion
- Jan 2025
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Rilzabrutinib with Placebo (2 arms). Primary endpoint: Percentage of Participants With Durable Platelet Response at 24 weeks. Started Dec 2020; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04562766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562766.